Clinical trial

Dose-escalating Trial With UniCAR02-T Cells and PSMA Target Module (TMpPSMA) in Patients With Progressive Disease After Standard Systemic Therapy in Cancers With Positive PSMA Marker

NCT04633148

Study summary

ClinicalTrials.gov

Dose-escalating Trial With UniCAR02-T Cells and PSMA Target Module (TMpPSMA) in Patients With Progressive Disease After Standard Systemic Therapy in Cancers With Positive PSMA Marker

Design: INTERVENTIONAL · Status: TERMINATED · Phase: PHASE1

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

4 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Unmapped registry intervention Cyclophosphamide (Non-IMP) Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Fludarabine (Non-IMP) Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention UniCAR02-T-pPSMA Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention UniCAR02-T (IMP) Find medicine records · Find other trials using this name

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2020-11-23

PhasePHASE1

Conditions

Prostate Cancerverified · MONDO: prostate cancer

Interventions

Cyclophosphamide (Non-IMP)DRUG

Fludarabine (Non-IMP)DRUG

UniCAR02-T-pPSMADRUG

UniCAR02-T (IMP)DRUG

Sponsors & collaborators

AvenCell Europe GmbHlead sponsor

PHARMALOG Institut für klinische Forschung GmbHcollaborator

Mapped research locations

HamburgGermany1 DresdenSaxony, Germany1 UlmBaden-Wurttemberg, Germany1 WürzburgBavaria, Germany1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04633148 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.